iCardiac acquires clinical trials division of nSpire Health

By Zachary Brennan contact

- Last updated on GMT

iCardiac acquires clinical trials division of nSpire Health

Related tags: Cardiac safety, Clinical trial

Cardiac safety assessment service provider iCardiac Technologies has added respiratory and ePRO services to its offerings through the acquisition of the clinical trials division of nSpire Health.

Financial terms of the acquisition were not disclosed. As part of the transaction, iCardiac has opened a new office in Longmont, Colorado to accommodate the project management, data management, customer support, IT, technology development and business development teams that are joining iCardiac from nSpire Health.  

Alex Zapesochny, president & CEO of iCardiac, told Outsourcing-Pharma.com that the acquisition is important “as we were trying to get onto preferred provider lists, [and it] became clear that it’s important that a single provider can do cardiac safety and the spirometry component​.” 

For the pharma companies that require spirometry, which Zapesochny said includes seven to 10 larger users, they often value being able to go to the same source for cardiac safety and spirometry. 

iCardiac and nSpire have worked side-by-side as closely-integrated partners for over five years and on over 20 clinical trials​," Zapesochny said. 

nSpire Health has conducted more than 225 clinical trials over the past decade, providing centralized spirometry, pulmonary diagnostics, challenge testing, eDiary and data management services for Phase I-IV studies. 

John Sage, who served as SVP of nSpire Health’s clinical division and will continue to lead respiratory and ePRO service operations at iCardiac, added: “Both current and future customers will benefit greatly from this combination of two service-oriented, technology-centered organizations​.” 

As far as future M&A, Zapesochny said that the company “will add some other small acquisitions in areas where we can add other services to CROs or sponsors​,” and they will be “complementary to what we already offer​.”

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers